ReviewPharmacoEconomics2015
Economic features of antibiotic resistance: the case of methicillin-resistant Staphylococcus aureus.
Review in PharmacoEconomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Article
- Costs Associated with Failure of Vancomycin Treatment for Pneumonia and Bacteremia Due to Methicillin-ResistantThe Canadian journal of hospital pharmacy · 2026Article
- Article
- Advances in combating antimicrobial resistance in MRSA: a comprehensive review on nanotechnology and phage therapy.Antonie van Leeuwenhoek · 2025Review
- Review
- Toxic Shock Syndrome Toxin-1 (TSST-1) inToxins · 2025Review
- Antimicrobial resistance in Malaysia: a cross-sectional study analysing trends and economic impacts.BMJ open · 2025Article
- Associations between total protein, globulin, and nasal Methicillin-ResistantFrontiers in immunology · 2025Article
- Combating Antimicrobial Resistance Through a Data-Driven Approach to Optimize Antibiotic Use and Improve Patient Outcomes: Protocol for a Mixed Methods Study.JMIR research protocols · 2024Article
- Molecular Evolution and Pathogenicity of Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Synergistic bactericidal activity of a novel dual β-lactam combination against methicillin-resistant Staphylococcus aureus.The Journal of antimicrobial chemotherapy · 2024Article
- News sequences types of Staphylococcus aureus isolated from human pathologicals fluids in Burkina Faso.BMC research notes · 2024Article
- The burden of antibiotic resistance of the main microorganisms causing infections in humans - review of the literature.Journal of medicine and life · 2024Review
- Diagnostic utility of nasal methicillin-resistantAntimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- Comprehensive Approaches for the Search and Characterization of Staphylococcins.Microorganisms · 2023Article
- Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Cinnamaldehyde ResistMolecules (Basel, Switzerland) · 2022Article
- Human Plasma Significantly Reduces Bacteriophage Infectivity Against Staphylococcus aureus Clinical Isolates.Cureus · 2022Article
- Effect of ZnO nanoparticles on methicillin, vancomycin, linezolid resistance and biofilm formation in Staphylococcus aureus isolates.Annals of clinical microbiology and antimicrobials · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper analyses and updates the economic information regarding methicillin-resistant Staphylococcus aureus (MRSA), including information that has been previously reviewed by other authors, and new information, for the purpose of facilitating health management and clinical decisions. The analysed articles reveal great disparity in the economic burden on MRSA patients; this is mainly due to the diversity of the designs of the studies, as well as the variability of the patients and the differences in health care systems. Regarding prophylactic strategies, the studies do not provide conclusive results that could unambiguously orientate health management. The studies addressing treatments noted that linezolid seems to be a cost-effective treatment for MRSA, mostly because it is associated with a shorter length of stay (LOS) in hospital. However, important variables such as antimicrobial susceptibility, infection type and resistance emergence should be included in these analyses before a conclusion is reached regarding which treatment is the best (most efficient). The reviewed studies found that rapid MRSA detection, using molecular techniques, is an efficient technique to control MRSA. As a general conclusion, the management of MRSA infections implicates important economic costs for hospitals, as they result in higher direct costs and longer LOS than those related to methicillin-susceptible S. aureus (MSSA) patients or MRSA-free patients; there is wide variability in those increased costs, depending on different variables. Moreover, the research reveals a lack of studies on other related topics, such as the economic implications of changes in MRSA epidemiology (community patients and lineages associated with farm animals).
Indexed as
Identifiers
25447195What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.